SCHEMBL5692115

SCHEMBL5692115

CN1CCN(c2cccc(NC(=O)Nc3csc(-c4ccncc4)n3)n2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 10/20 1.00
CDK5R1 Q15078 10/20 1.00
DYRK1A Q13627 2/20 0.50
CCNA2 P20248 4/20 0.45
CDK2 P24941 4/20 0.45
CCNA1 P78396 4/20 0.45
ROCK1 Q13464 1/20 0.45
IRAK4 Q9NWZ3 2/20 0.43
CHEK1 O14757 1/20 0.41
GSK3B P49841 2/20 0.41
WNT1 P04628 1/20 0.41
CLK2 P49760 1/20 0.40
GSK3A P49840 1/20 0.40
CSNK2A1 P68400 1/20 0.40
STK3 Q13188 1/20 0.40
HIPK4 Q8NE63 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
HTR3E A5X5Y0 2/20 0.40
HTR3B O95264 2/20 0.40
HTR3A P46098 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5342940 0.90 CDK5 (0.82) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5690422 0.89 CDK5 (0.81) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5348793 0.89 CDK5 (0.80) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5345136 0.89 CDK5 (0.80) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5341693 0.89 CDK5 (0.80) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5347774 0.88 CDK5 (0.78) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5347393 0.88 CDK5 (0.78) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5341603 0.87 CDK5 (0.77) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5346446 0.86 CDK5 (0.75) CDK5CDK5R1DYRK1ACCNA2CDK2
SCHEMBL5345330 0.85 CDK5 (0.74) CDK5CDK5R1DYRK1ACCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309589-B1 UREA COMPOUNDS AND METHODS OF USES AMGEN INC (US) 2006-03-15 EP claimed
EP-1309589-A2 UREA COMPOUNDS AND METHODS OF USES Amgen Inc. (US) 2003-05-14 EP claimed
US-20020173507-A1 Urea compounds and methods of uses AMGEN INC. 2002-11-21 US claimed
WO-2002014311-A2 UREA COMPOUNDS AND METHODS OF USES AMGEN INC. (US) 2002-02-21 WO claimed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1309589-B1 UREA COMPOUNDS AND METHODS OF USES AMGEN INC (US) 2006-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173507-A1 Urea compounds and methods of uses SLC14A1, UMPS, BAX CDK5 40/4885CDK5R1 244/4885DYRK1A 3515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.